AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00930293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram hydrobromide
Description: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day
Study NCT03280602 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tension band wiring (TBW)
Description: 2 x K-wire fixation (1.6 mm) and wire cerclage.
Study NCT03280602 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plate fixation
Description: Olecranon fractures in this arm are fixed with Synthes´ VA-LCP Olecranon Plates 2.7/3.5.
Study NCT04429217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immediate post-operative complete weight-bearing after surgery
Description: Patients randomized to the experimental post-operative rehabilitation intervention will undergo to immediate complete weight-bearing starting immediately after surgery. Immediate complete weight-bearing consists in the possibility to undergo all the everyday activities without limiting weight-bearing and without the use of walking aids.~During the rehabilitation period, patients will wear an ankle brace (VACOankle® OPED); this will ensure the safety of the early recovery phases, protecting from dangerous movements while allowing the mobilization in the healthy range of movement.
Study NCT04429217 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: delayed weight-bearing for 6 weeks after surgery
Description: Patients randomized to the control post-operative rehabilitation intervention will undergo to delayed weight-bearing starting at 6-weeks post-operatively. Delayed weight-bearing consists in the limitation of the weight-bearing to 20-30% of patient's total weight using crutches for the first 6 weeks after surgery.~During the rehabilitation period, patients will wear an ankle brace (VACOankle® OPED).
Study NCT01280981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Tranexamic acid at an oral dose of 1.3 g administered 3 times per day for up to 5 days (maximum of 15 doses) during menstruation for 9 menstrual periods.
Study NCT00508378 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview regarding side-effects of chemotherapy, 30-45 minutes.
Study NCT01630161 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard care includes routine assessment of smoking behavior and brief clinical intervention. Smoking counseling for all participants in the current study will be completed by a Certified Tobacco Treatment Specialist consisting consists of brief counseling (\<15 minutes) based on the 5 A's Clinical Practice Guidelines; Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, Arrange for follow-up (Fiore et al., 2008). Patients receive information for local and state smoking resources (e.g., Quitline), pharmacotherapy options, and if interested, assistance with obtaining a prescription for pharmacotherapy. Follow-up with patients occurs at 2-weeks, only among those who are prescribed smoking medications (i.e., Varenicline, Bupropion).
Study NCT01630161 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Relapse Prevention for Cancer Patients (SRP-CaP)
Description: The proposed multimodal intervention consists of a series of easy-to-read relapse prevention booklets (Forever Free) that have shown to be efficacious with a general smoking population (Brandon et al., 2000; 2004), and digital video disk (DVD) customized to the needs of cancer patients (to be developed in Year One).
Study NCT00508378 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Quality of life survey and symptom assessment questionnaire, 15 minutes.
Study NCT04112043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking Exercise
Description: Participants randomized to this intervention 3 days/week of supervised, center-based walking exercise.
Study NCT04112043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Riboside (NR)
Description: Participants randomized to this intervention will receive 1,000 mg/day of NR.
Study NCT00595855 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trabeculectomy
Description: Cairns-like trabeculectomy, limbus based, with 5_FU supplementation and argon laser suturelysis
Study NCT00595855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deep sclerectomy
Description: deep sclerectomy with no implant and no sutures to the superficial flap, limbus based with suppplementation of FU (if needed)
Study NCT01344824 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: bevacizumab
Description: 15 mg/kg once per 21 day cycle (up to 4 cycles).
Study NCT01344824 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: carboplatin
Description: Area Under the Curve (AUC)=6, once every 21 day cycle (up to 4 cycles)
Study NCT01344824 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: erlotinib hydrochloride
Description: 150mg, daily for 21 day cycle (up to 4 cycles)
Study NCT01344824 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pemetrexed disodium
Description: 500 mg/m2 on day 1 of a 21 day cycle (up to 4 cycles)
Study NCT00322309 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for days 1-4 Placebo for days 5-9 Placebo for days10-78 Placebo for days 79-81 Placebo for days 82-84
Study NCT00322309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Days 1-4 15mg Days 5-9 30 mg Days 10-78 45mg Days 79-81 30mg Days 82-84 15mg
Study NCT03259425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab at a dose of 240 mg given as an IV infusion starting on day 0. It will be given every 14 days for a total of 7 infusions; Then participant will undergo surgery. Nivolumab will then be administered at a flat dose of 480 mg IV every 28 days for up to one year.
Study NCT04468438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum estrogen and urinary albumin creatinine ratio
Description: serum estrogen and urinary albumin creatinine ratio
Study NCT03259425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF10
Description: 1 x 107th TCID50/mL, intratumoral injection to a single or multiple eligible tumors for a total of 5 mL; on days 0, 7, 14, 21, 28, 42, 56, 70, 84 for a total of 9 injections. All eligible tumors except one will be treated with HF10 up to the maximum volume allowed. The untreated tumor will be used as an untreated control lesion.
Study NCT00673972 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: gastric scintigraphy
Description: All tests start after overnight fast. Test meals consists of 120g scrambled egg, two slices of toasted bread, 30g of strawberry jam and 120ml of water. 12MBg (0.33mCi) of 99mTc sulfur colloid is mixed with egg thoroughly before the mixture cooked in a microwave oven for 2 minutes. All meals are prepared on the morning of examination and consumed within 20 minutes.~Anterior and posterior images of the gastric region are taken within one minute after completion of test meals. Subsequent images are taken every 2 minutes in the first 60 minutes and at 120 minutes and 180 minutes. One-min images of gastric region at upright position are taken in the 140keV 99mTc peak with a 20% window.
Study NCT01514292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring of glucose levels (Dexcom)
Description: Manipulation of glucose levels during multiple clinic days. Achieved through diet, exercise and insulin regimen defined in protocol.Evaluation of CGM performance characteristics in reference to a laboratory standard.
Study NCT02432612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Sativex is supplied as a liquid containing 27 mg/mL Δ9-tetrahydrocannabinol (THC) and 25 mg/mL Cannabidiol (CBD) plus peppermint flavoring. Each 100 µL actuation of the pump-action spray delivers 100 µL 27 mg THC and 25 mg CBD.
Study NCT03436628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyT1DHero
Description: A mobile phone application
Study NCT04528095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Clozapine 400 \~ 600mg/d or plasma concentration >350ng/ml Amisulpride 200-800mg/d Gingke biloba 120-360mg/d
Study NCT04528095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MECT
Description: MECT:The treatment lasted for 4 months,16 times in total MST:The treatment lasted for 4 months,16 times in total
Study NCT04528095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS
Description: Two electrode emplacement groups (target nucleus accumbens and hippocampus respectively)
Study NCT04741360 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Modified Story Memory Technique
Description: 10-session computerized program to improve new learning and memory
Study NCT04741360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Story Memory Technique
Description: 10-session computerized program to improve new learning and memory
Study NCT03867591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastro-AD®
Description: The product under study is Gastro-AD® fermented soy powder in the form of orodispersible flavored powder packed in non-transparent sachets.~Content: 1 g of Gastro-AD® powder per sachet + flavoring agents.
Study NCT03867591 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product will have very similar appearance, color, texture and taste as the Gastro-AD® flavored sachet. The placebo sachets contain the respective amount of maltodextrin (1 g) and exactly the same flavoring and coloring agents as Gastro-AD® powder flavored sachets.
Study NCT01441271 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ileal diversion and lavage
Description: The surgical approach involves an attempted laparoscopic creation of a loop ileostomy after visually assessing the colon to assure viability. If the loop is unable to be safely performed laparoscopically an open loop ileostomy will be performed. Intraoperatively, 8 liters of warmed polyethylene glycol 3350/electrolyte solution \[GoLytely®; Braintree Laboratories\] will be infused into the colon via the ileostomy and collected via a rectal drainage tube. Post-operatively, the patients will receive antegrade vancomycin flushes \[500 mg in 500 ml of Lactated Ringers; q8 hours for duration of 10 days\] via a Malecot catheter \[24 French\] left in the efferent limb of the ileostomy (Figure 1). Additionally patients will be continued on intravenous metronidazole \[500mg q8 hours\] for 10 days.
Study NCT01441271 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total abdominal colectomy
Description: The surgical approach of the colon in a total abdominal colectomy involves a midline incision. The complete colon in the abdomen (from ileum to rectum) will be removed and an end ileostomy is performed.
Study NCT03818958 — intervention group
Intervention type: OTHER
Intervention: blood sampling
Description: blood sampling
Study NCT02277652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Miller Laryngoscope
Description: Direct laryngoscopy
Study NCT02277652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Bonfils intubation fibrescope
Description: Optical laryngoscopy
Study NCT02277652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The GlideScope Ranger
Description: Videolaryngoscopy
Study NCT03850496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revitive IX Neuromuscular Stimulation Device
Description: Neuromuscular stimulation footplate device with a pre-programmed 30 minute varying electrical stimulation sequence.
Study NCT00676364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% lidocaine topical anesthetic cream
Description: A dollop of 4% lidocaine cream was applied under occlusive dressing for 15 mins prior to venipuncture
Study NCT00676364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: A dollop of matching placebo cream was applied under occlusive dressing for 15 mins prior to venipuncture
Study NCT01476878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frameless Stereotactic Radiosurgery with radiation mask
Description: Linac-based radiosurgery using a thermoplastic mask (single treatment)
Study NCT02169375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain computer Interface Mu (SMR) rhythm
Description: Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 10 sessions.
Study NCT00785655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermacyd PH_DETINLYN (Lactic Acid)
Study NCT04321226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond Laser guided Arcuate Keratotomy
Description: Astigmatism will be reduced in cataract surgery using a low energy Femtosecond Laser device
Study NCT03163498 — intervention group
Intervention type: OTHER
Intervention: No intervantion. It´s a Cross-Sectional Study
Description: No intervential
Study NCT02203227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02203227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioTurmin (Curcuma longa rhizomes extract)
Study NCT02203227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioTurmin-WD (Water dispersible curcuminoids)
Study NCT01832116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-MMOT0530A
Description: Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
Study NCT02472964 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 8mg/kg Iv over 90 minutes x 1 then Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
Study NCT02472964 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MYL- 1401O
Description: MYL-1401O 8mg/kg Iv over 90 minutes x 1 then HERMyl 1401O Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
Study NCT02472964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80mg/m2 IV over 60 minutes weekly.
Study NCT02472964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80mg/m2 IV over 60 minutes weekly.
Study NCT02203227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MaQxan
Study NCT02504827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime/avibactam
Description: Ceftazidime/avibactam 2.5gm iv q8h for 3 doses
Study NCT02586038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Study NCT02586038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02586038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02586038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Study NCT03731819 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abbreviated PB MRI
Description: Abbreviated PB MRI which targets table time of 10 minutes. For MRI acquisition, standard dose of commercially available MR contrast agent (Gadovist, Bayer, Germany) is used on weight-based dosing (0.1mmol/kg).
Study NCT04549090 — intervention group
Intervention type: DRUG
Intervention: QL (quadratus lumborum) block administration
Description: Fo the QL block group, they will be receiving bilateral QL block. A total of 40ml of 0.25% bupivacaine (Marcaine) and 10ml of liposomal bupivacaine (Exparel) will be administered
Study NCT01743560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
Study NCT01743560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were to be treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
Study NCT01686126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Description: Intrauterine device
Study NCT02472964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 IV over 60 minutes on day 1 of a 3 week cycle
Study NCT02472964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 IV over 60 minutes on day 1 of a 3 week cycle
Study NCT01215292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 mcg/kg on Day 1
Study NCT01215292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acyline
Description: 300 mcg/kg on Day 1
Study NCT01215292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: 5 gm of 1% T Gel applied transdermally for 10 days
Study NCT01215292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone gel
Description: 5 gm of 1% T Gel applied transdermally for 10 days
Study NCT01686126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: oral medication
Study NCT01059422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir; Abacavir/Lamivudine
Description: Raltegravir: 400 mg twice daily Abacavir/Lamivudine fixed-dose combination: 600mg/300mg once daily
Study NCT01215292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole 400
Description: 400 mg PO daily, Days 3-10
Study NCT01215292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole 800
Description: 800 mg PO daily, Day 3-10
Study NCT01215292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: 2.5 mg PO daily, Day 3-10
Study NCT01215292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg PO daily, Day 3-10
Study NCT01215292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ketoconazole
Description: placebo to mimic ketoconazole
Study NCT02154763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study NCT02154763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study NCT03869398 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tums
Description: start their calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
Study NCT03869398 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: start their calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
Study NCT04534374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Barbell back squat, press, and deadlift for three sets of five repetitions with the weight closest to 75% of their estimated 1 repetition max. The participants were instructed to execute the movement with moderate speed (2s eccentric, 2s concentric, no pause in between). The rest period between sets and exercise movements was two to three minutes.
Study NCT04534374 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercise (sham exercise)
Description: Participants completed a passive stretching exercise session for a similar duration of time as the resistance exercise (≈ 30 min) as sham intervention, which included 15-20 stretching movements twice, holding each for 30 seconds as recommended by ACSM.
Study NCT02660827 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin Pump
Description: Closed Loop Algorithm
Study NCT03102723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: 1. Cangrelor treatment: IV Cangrelor as a single IV bolus (30 μg/kg) followed by an infusion (4 μg/kg/min) of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI. This dosing regimen is identical to that used in the CHAMPION trials.~   Or~2. Placebo control: IV normal saline as a single IV bolus followed by an infusion of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI.